Moxifloxacine Eg

Moxifloxacin, the active ingredient in Moxifloxacine Eg, is a fluoroquinolone antibiotic presented as an oral tablet for oral use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute sinusitis, acute exacerbations of chronic bronchitis, skin and soft‑tissue infections, and intra‑abdominal infections in adult patients.

GNH USA supplies Moxifloxacine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers across.

Moxifloxacin is indicated for several bacterial infections affecting the respiratory tract, skin, and intra‑abdominal sites.

Community‑acquired bacterial pneumonia: provides effective bacterial eradication and clinical improvement in adult patients. Acute bacterial sinusitis: reduces sinus inflammation and resolves infection symptoms. Acute bacterial exacerbation of chronic bronchitis: shortens duration of cough and improves lung function. Skin and skin structure infections: achieves bacterial clearance in cellulitis, abscesses, and wound infections. Intra‑abdominal infections: contributes to resolution of complicated infections such as peritonitis and intra‑abdominal abscesses.

Moxifloxacin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertigo or light‑headedness. - Abdominal pain: cramping or discomfort. - Rash: mild skin eruption.

Serious or Rare Side Effects: - Tendon rupture: risk of Achilles or other tendon tears, especially in older adults. - QT interval prolongation: may lead to cardiac arrhythmias in susceptible patients. - Severe hypersensitivity: includes Stevens‑Johnson syndrome, toxic epidermal necrolysis, or anaphylaxis.

When prescribing moxifloxacin, clinicians should consider several precautionary measures to minimize risks. - Renal impairment: adjust therapy and monitor renal function in patients with reduced clearance. - Hepatic disease: use cautiously and observe liver enzymes. - History of tendon disorders: avoid in patients with prior tendon injury or those on corticosteroids. - Cardiac risk: assess QT prolongation potential, especially with electrolyte disturbances. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antacids containing aluminium or magnesium: chelate the drug and markedly reduce absorption. - CYP1A2 inhibitors (e.g., fluvoxamine): increase plasma concentrations, raising toxicity risk. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of central nervous system stimulation. - QT‑prolonging agents (e.g., macrolides, antiarrhythmics): additive effect on cardiac repolarization. - Theophylline: possible increased serum levels, monitor for toxicity.